Cardiotoxic Effects of Chemotherapy in Patients with Sarcomas


About this study

The purpose of this study is to determine if two-dimensional speckle tracking echocardiography (2D-STE) derived-strain can detect early myocardial dysfunction and thus predict cardiotoxicity in sarcoma subjects undergoing anthracycline therapy and to compare three dimensional speckle tracking echocardiography (3D-STE) to 2D-STE in the same group of patients.

Participation eligibility

Participant eligibility includes age, gender, type and stage of disease, and previous treatments or health concerns. Guidelines differ from study to study, and identify who can or cannot participate. There is no guarantee that every individual who qualifies and wants to participate in a trial will be enrolled. Contact the study team to discuss study eligibility and potential participation.

Inclusion Criteria:

  • Patients followed at Mayo Clinic and treated for sarcoma with doxorubicin as first-line treatment.

Exclusion Criteria: 

  • First-line treatment not including doxorubicin
  • Treatment performed outside of Mayo Clinic with different protocols
  • Age <18 years
  • Prisoners
  •  Subjects unable or unwilling to provide the written consent
  • LVEF <50%,

Participating Mayo Clinic locations

Study statuses change often. Please contact the study team for the most up-to-date information regarding possible participation.

Mayo Clinic Location Status Contact

Rochester, Minn.

Mayo Clinic principal investigator

Hector Villarraga, M.D.

Open for enrollment

Contact information:

Hector Villarraga M.D.


More information


Publications are currently not available

Additional contact information

Cancer-related trials contact form

Phone: 855-776-0015 (toll-free)

International patient clinical studies questions